GSK plc 6-K, filed Nov 12, 2021
GSK plc (GSK)
6-K
2021-11-12
For: 2021-11-12
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on November 12, 2021.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of November 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 12 November 2021, London UK and San Francisco,
U.S.
Primary endpoint met in COMET-TAIL Phase III trial evaluating
intramuscular administration of sotrovimab for early treatment of
COVID-19
●
COMET-TAIL Phase III data demonstrated
that intramuscular administration of sotrovimab was non-inferior
and offered similar efficacy to intravenous administration for
high-risk populations
●
The trial enrolled participants during
the Delta variant wave of the pandemic in the
US
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc.
(Vir) (Nasdaq: VIR) today
announced headline data from the randomised, multi-centre,
open-label COMET-TAIL Phase III trial, which achieved its primary
endpoint, demonstrating intramuscular (IM) administration of
sotrovimab was non-inferior to intravenous (IV) administration for
the early treatment of mild-to-moderate COVID-19 in high-risk,
non-hospitalised adults and adolescents (12 years of age and
older).
The COMET-TAIL Phase III trial was designed to evaluate the
efficacy, safety, and tolerability of sotrovimab delivered via IM
administration compared to IV administration in high-risk patients
up to seven days after symptom onset. In the IM administration
(500mg) arm of the trial, there was a 2.7% rate of progression to
hospitalisation for more than 24 hours or death through Day 29 of
the trial, compared to 1.3% in the IV administration arm (also
500mg). The adjusted difference between the IM and IV arms of the
trial was 1.07% with a 95% confidence interval (CI) of -1.25% to
3.39%. The upper bound of the 95% CI is within the predetermined
3.5% non-inferiority margin set for the trial's primary endpoint in
consultation with the US Food and Drug Administration
(FDA).
In addition, there were low rates of serious adverse events and
Grade 3-4 adverse events (≤1% in both arms, for both
measures) observed in the headline data.
The companies plan to progress regulatory submissions globally,
including ongoing discussions with the FDA regarding the existing
Emergency Use Authorization for sotrovimab.
Dr Hal Barron, Chief Scientific Officer and President,
said: "I am pleased that
today's results demonstrated similar efficacy for sotrovimab when
injected directly into the muscle compared to administered
intravenously, potentially offering a more convenient option for
patients. We look forward to working with regulatory authorities to
help make this new option available to appropriate patients with
COVID-19."
George Scangos, Ph.D., chief executive officer of Vir,
said: "This trial was
conducted during the height of circulation of the Delta variant,
with significant enrollment in Florida - a hot spot for this
particular variant and where hospitalisation rates averaged more
than 10 percent of confirmed cases. We designed sotrovimab to stand
up to the variants that we anticipated would occur, and these data
demonstrate that sotrovimab administered via IV or IM could prove
important in the fight against COVID-19 following authorisation. As
we approach the third year of the pandemic, we can expect that
multiple treatment options will continue to be needed, particularly
for high-risk patients with complex health
needs."
Today's update follows announcements in the first half of 2021
regarding the COMET-ICE Phase III trial, which investigated IV
infusion of sotrovimab in adults with mild or moderate
COVID-19 at high-risk of progression to severe disease. The
final COMET-ICE trial results in the full study
population of 1057 participants, demonstrated a
79% reduction in hospitalisation and death at Day
29 vs placebo.
About sotrovimab
Sotrovimab is an investigational SARS-CoV-2 neutralising monoclonal
antibody. The antibody binds to an epitope on SARS-CoV-2 that is
shared with SARS-CoV-1 (the virus that causes SARS), indicating
that the epitope is highly conserved, which may make it more
difficult for resistance to develop. Sotrovimab, which incorporates
Xencor's Xtend™ technology, has also been designed to achieve
high concentration in the lungs to ensure optimal penetration into
airway tissues affected by SARS-CoV-2 and to have an extended
half-life.
Updated in vitro data, published in bioRxiv,
demonstrate that sotrovimab retains activity against all current
variants of concern and interest of the SARS-CoV-2 virus as defined
by the World Health Organisation, plus others, including, but not
limited to, Delta (B.1.617.2), Delta Plus (AY.1 or AY.2) and Mu
(B.1.621).
About the sotrovimab clinical development programme
● COMET-ICE: a Phase III, multi-centre,
double-blind, placebo-controlled trial investigated intravenous
(IV) infusion of sotrovimab in adults with mild-to-moderate
COVID-19 at high-risk of progression to severe disease, who are not
hospitalised and not requiring oxygen. The final COMET-ICE trial
results in the full trial population of 1,057 participants
demonstrated a 79% reduction (adjusted relative risk reduction)
(p<0.001) in hospitalisation for more than 24 hours or death due
to any cause by Day 29 compared to placebo, meeting the primary
endpoint of the trial. Interim data were published
in The
New England Journal of Medicine on October 27, 2021 and final data were
pre-published on November 8, 2021 on medRxiv.
● COMET-TAIL: a
Phase III randomised, multi-centre, open label, non-inferiority
trial of intramuscular (IM) versus intravenous (IV)
administration of sotrovimab for the early treatment of
mild-to-moderate COVID-19 in high-risk non-hospitalised adult and
paediatric patients (12 years of age and older). The trial's
primary endpoint was met, and headline data demonstrated that
intramuscularly administered sotrovimab was non-inferior and
offered similar efficacy to intravenous administration for
high-risk populations. The COMET-TAIL trial enrolled a
total of 983 patients up to seven days after onset of symptoms. The
trial originally included three arms: 500mg of sotrovimab
given intravenously, and two intramuscular arms, consisting of
500mg and a low dose of 250mg. An independent safety monitoring
committee recommended enrolment in the 250mg arm be discontinued
after a greater number of hospitalisations in that arm was noted.
The 500mg dose arms were recommended to continue with enrolment as
planned. The companies plan to submit the full COMET-TAIL data set
to a peer-reviewed journal for publication in the first
quarter of 2022.
● COMET-PEAK: a Phase II randomised, multi-centre,
parallel group trial evaluating IV and IM administration of
sotrovimab in outpatients with mild-to-moderate COVID-19. Data
available to date from open label Part B of the trial (500mg IV vs.
500mg IM) demonstrated equivalence on the virological response
between the IM and IV arms, while also showing an acceptable
tolerability profile for IM with only 10/82 participants (12%)
reporting any injection site reaction, all of which were low grade
(Grade 1). The companies plan to submit the full COMET-PEAK
data set to a peer-reviewed journal for
publication.
● GSK and Vir are also partnering to investigate the
use of sotrovimab in uninfected immunocompromised adults to
determine whether sotrovimab can prevent symptomatic COVID-19
infection. GSK and Vir are supporting investigator sponsored
studies and fostering scientific collaborations with both
experienced investigators and networks, who are involved in the
continuum of care of immunocompromised patients, to understand the
role sotrovimab for prophylaxis could play in this population.
Discussions with regulatory authorities regarding the prophylaxis
program will take place in due course.
About global access to sotrovimab
● Sotrovimab is authorised for emergency use in the
United States and received a positive scientific
opinion under
Article 5(3) of Regulation 726/2004 from the Committee for Human
Medicinal Products (CHMP) in the EU. Sotrovimab has been granted a
provisional marketing authorisation in Australia and a conditional
marketing authorisation in Saudi Arabia. In Japan it has been
approved via the Special Approval for Emergency Pathway. Temporary
authorisations have been granted in Bahrain, Brazil, Canada, Egypt,
Italy, Kuwait, Oman, Qatar, Singapore, Switzerland, Thailand and
the United Arab Emirates.
● Sotrovimab is supplied in several countries around
the world, including through national agreements in the United
States, Japan, Australia, Canada, Singapore and UAE. We have also
signed a Joint Procurement Agreement with the European Commission
to supply doses of sotrovimab. Additional agreements are yet to be
announced due to confidentiality or regulatory
requirements.
Sotrovimab in the United States
The following is a summary of information for sotrovimab.
Healthcare providers in the U.S. should review the Fact Sheets for
information about the authorised use of sotrovimab and mandatory
requirements of the EUA. Please see the FDA Letter of
Authorisation,
full Fact Sheet for
Healthcare Providers, and
full Fact Sheet for
Patients, Parents, and Caregivers.
Sotrovimab has been authorized by the U.S. FDA for the
emergency use described below. Sotrovimab is not FDA-approved
for this use.
Sotrovimab is authorized only for the duration of the
declaration that circumstances exist justifying the authorization
of the emergency use of sotrovimab under section
564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the
authorization is terminated or revoked sooner.
Authorized Use
The U.S. Food and Drug Administration (FDA) has issued an Emergency
Use Authorization (EUA) to permit the emergency use of the
unapproved product sotrovimab for the treatment of mild-to-moderate
coronavirus disease 2019 (COVID-19) in adults and pediatric
patients (12 years of age and older weighing at least
40 kg) with positive results of direct SARS-CoV-2 viral
testing, and who are at high risk for progression to severe
COVID-19, including hospitalization or death.
Limitations of Authorized Use
Sotrovimab is not authorized for use in patients:
●
who are hospitalized due
to COVID-19, OR
●
who require oxygen
therapy due to COVID-19, OR
●
who require an increase
in baseline oxygen flow rate due to COVID-19 (in those on chronic
oxygen therapy due to underlying non-COVID-19 related
comorbidity)
Benefit of treatment with sotrovimab has not been observed in
patients hospitalized due to COVID-19. SARS-CoV-2 monoclonal
antibodies may be associated with worse clinical outcomes when
administered to hospitalized patients with COVID-19 requiring high
flow oxygen or mechanical ventilation.
Important Safety Information
CONTRAINDICATIONS
Sotrovimab is contraindicated in patients who have a history of
anaphylaxis to sotrovimab or to any of the excipients in the
formulation.
WARNINGS AND PRECAUTIONS
There are limited clinical data available for sotrovimab. Serious
and unexpected adverse events may occur that have not been
previously reported with sotrovimab use.
Hypersensitivity Including Anaphylaxis and Infusion-Related
Reactions
Serious hypersensitivity reactions, including anaphylaxis, have
been observed with administration of sotrovimab. If signs and
symptoms of a clinically significant hypersensitivity reaction or
anaphylaxis occur, immediately discontinue administration and
initiate appropriate medications and/or supportive
care.
Infusion-related reactions, occurring during the infusion and up to
24 hours after the infusion, have been observed with administration
of sotrovimab. These reactions may be severe or life
threatening.
Signs and symptoms of infusion-related reactions may include:
fever, difficulty breathing, reduced oxygen saturation, chills,
fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia,
bradycardia), chest pain or discomfort, weakness, altered mental
status, nausea, headache, bronchospasm, hypotension, hypertension,
angioedema, throat irritation, rash including urticaria, pruritus,
myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness
and diaphoresis.
Consider slowing or stopping the infusion and administer
appropriate medications and/or supportive care if an
infusion-related reaction occurs.
Hypersensitivity reactions occurring more than 24 hours after the
infusion have also been reported with the use of SARS-CoV-2
monoclonal antibodies under Emergency Use
Authorization.
Clinical Worsening After SARS-CoV-2 Monoclonal Antibody
Administration
Clinical worsening of COVID-19 after administration of SARS-CoV-2 monoclonal
antibody treatment has been reported and may include signs or
symptoms of fever, hypoxia or increased respiratory difficulty,
arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia),
fatigue, and altered mental status. Some of these events required
hospitalization. It is not known if these events were related to
SARS-CoV-2 monoclonal antibody use or were due to progression of
COVID-19.
Limitations of Benefit and Potential
for Risk in Patients with Severe COVID-19
Benefit of treatment with sotrovimab has not been observed in
patients hospitalized due to COVID-19. SARS-CoV-2 monoclonal antibodies may be
associated with worse clinical outcomes when administered to
hospitalized patients with COVID-19 requiring high flow oxygen or mechanical
ventilation. Therefore, sotrovimab is not authorized for use in
patients: who are hospitalized due to COVID-19, OR who require oxygen therapy due to
COVID-19, OR who require an increase in baseline oxygen
flow rate due to COVID-19 in those on chronic oxygen therapy due to
underlying non-COVID-19 related comorbidity.
ADVERSE EVENTS
Hypersensitivity adverse reactions have been observed in 2% of
patients treated with sotrovimab and 1% with placebo in
COMET-ICE.
The most common treatment-emergent adverse events observed in the
sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea
(2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No
other treatment-emergent adverse events were reported at a higher
rate with sotrovimab compared to placebo.
USE IN SPECIFIC POPULATIONS
Pregnancy
There are insufficient data to evaluate a drug-associated risk of
major birth defects, miscarriage, or adverse maternal or fetal
outcome. Sotrovimab should be used during pregnancy only if the
potential benefit justifies the potential risk for the mother and
the fetus.
Lactation
There are no available data on the presence of sotrovimab in human
milk, the effects on the breastfed infant, or the effects on milk
production. Individuals with COVID-19 who are breastfeeding should
follow practices according to clinical guidelines to avoid exposing
the infant to COVID-19.
About the Vir and GSK Collaboration
In April 2020, Vir and GSK entered into a collaboration to research
and develop solutions for coronaviruses, including SARS-CoV-2, the
virus that causes COVID-19. The collaboration uses Vir's
proprietary monoclonal antibody platform technology to accelerate
existing and identify new anti-viral antibodies that could be used
as therapeutic or preventive options to help address the current
COVID-19 pandemic and future outbreaks. The companies will leverage
GSK's expertise in functional genomics and combine their
capabilities in CRISPR screening and artificial intelligence to
identify anti-coronavirus compounds that target cellular host
genes. They will also apply their combined expertise to research
SARS-CoV-2 and other coronavirus vaccines.
GSK Commitment to Tackling COVID-19
GSK's response to COVID-19 has been one of the broadest in the
industry, with potential treatments in addition to our vaccine
candidates in development with partner organisations.
GSK is collaborating with several organisations on COVID-19
vaccines by providing access to our adjuvant
technology. We are working
with Sanofi, Medicago and SK bioscience
to develop adjuvanted, protein-based vaccine candidates,
and all are now in Phase III clinical
trials. The use of an adjuvant can be of particular importance in a
pandemic since it may reduce the amount of vaccine protein required
per dose, allowing more vaccine doses to be produced and
contributing to protect more people in need.
GSK is also working with mRNA specialist, CureVac, to jointly
develop next generation, optimised mRNA vaccines for COVID-19 with
the potential to address multiple emerging variants in one
vaccine.
GSK is also exploring treatments for COVID-19 patients,
collaborating with Vir Biotechnology to investigate monoclonal
antibodies that could be used as therapeutic or preventive options
for COVID-19.
Vir's Commitment to COVID-19
Vir was founded with the mission of addressing the world's most
serious infectious diseases. In 2020, Vir responded rapidly to the
COVID-19 pandemic by leveraging our unique scientific insights and
industry leading antibody platform to explore multiple monoclonal
antibodies as potential therapeutic or preventive options for
COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir
advanced into the clinic. It was carefully selected for its
demonstrated promise in preclinical research, including an
anticipated high barrier to resistance and potential ability to
both block the virus from entering healthy cells and clear infected
cells. Vir is continuing to pursue novel therapeutic and
prophylactic solutions to combat SARSCoV-2 and future coronavirus
pandemics, both independently and in collaboration with its
partners.
About GSK
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused
on combining immunologic insights with cutting-edge technologies to
treat and prevent serious infectious diseases. Vir has assembled
four technology platforms that are designed to stimulate and
enhance the immune system by exploiting critical observations of
natural immune processes. Its current development pipeline consists
of product candidates targeting COVID-19, hepatitis B virus,
influenza A and human immunodeficiency virus. For more information,
please visit www.vir.bio.
|
GSK enquiries:
|
|
|
|
|
Media enquiries:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Simon Moore / Madeleine Breckon
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kristen Neese
|
+1 804 217 8147
|
(Philadelphia)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Analyst/Investor enquiries:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
Sonya Ghobrial
|
+44 (0) 7392 784784
|
(Consumer)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Vir Biotechnology Contacts:
Heather Rowe
Armstrong
Cara Miller
VP, Investor Relations
VP, Corporate Communications
harmstrong@vir.bio cmiller@vir.bio
+1 415 915
4228
+1 415 941 6746
GSK cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2020, GSK's Q3 Results and any
impacts of the COVID-19 pandemic.
Vir Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Words such as "may," "will," "plan," "potential," "aim,"
"promising" and similar expressions (as well as other words or
expressions referencing future events, conditions or circumstances)
are intended to identify forward-looking statements. These
forward-looking statements are based on Vir's expectations and
assumptions as of the date of this press release. Forward-looking
statements contained in this press release include, but are not
limited to, statements regarding the ability of sotrovimab to treat
and/or prevent COVID-19 either through IV or IM administration,
Vir's collaboration with GSK, plans to progress
regulatory submissions globally, including with the FDA regarding
the existing EUA for sotrovimab, planned discussions with other global regulatory
agencies, the timing of availability of clinical data, program
updates and data disclosures, the clinical development program for
sotrovimab, and the ability of sotrovimab to maintain activity
against circulating variants of concern and interest. Many factors
may cause differences between current expectations and actual
results, including unexpected safety or efficacy data observed
during preclinical or clinical studies, challenges in the treatment
of hospitalized patients, difficulties in collaborating with other
companies or government agencies, challenges in accessing
manufacturing capacity, successful development and/or
commercialization of alternative product candidates by Vir's
competitors, changes in expected or existing competition, delays in
or disruptions to Vir's business or clinical trials due to the
COVID-19 pandemic, geopolitical changes or other external factors,
and unexpected litigation or other disputes. Other factors that may
cause actual results to differ from those expressed or implied in
the forward-looking statements in this press release are discussed
in Vir's filings with the U.S. Securities and Exchange Commission,
including the section titled "Risk Factors" contained therein.
Except as required by law, Vir assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes
available.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
###
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date:
November 12, 2021
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|